[시장보고서]세계의 POCT(Point-of-Care Testing) 시장 : 제품, 검사 유형, 적응증, 기술, 샘플 유형, 구입 형태, 최종사용자, 유통 채널, 지역별

세계의 POCT(Point-of-Care Testing) 시장 : 제품, 검사 유형, 적응증, 기술, 샘플 유형, 구입 형태, 최종사용자, 유통 채널, 지역별 - 시장 규모, 산업 역학, 기회 분석, 예측(2025-2033년)

Global Point-of-Care Testing Market: By product, Test Type, Indication, Technology, Sample Type, Mode of Purchase, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033

상품코드 : 1804277

리서치사 : Astute Analytica

발행일 : 2025년 07월

페이지 정보 : 영문 260 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,250

￦ 6,151,000

PDF (Single User License)

PDF 보고서를 1명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 및 인쇄가 불가능합니다.

US $ 5,250

￦ 7,598,000

PDF & Excel (Multi User License)

PDF & Excel 보고서를 7명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능하며, 인쇄는 불가능합니다.

US $ 6,400

￦ 9,263,000

PDF, Excel & PPT (Corporate User License)

PDF, Excel 및 PPT 보고서를 동일 기업 내 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 및 인쇄가 가능합니다.

한글목차

샘플 요청 목록에 추가

세계 POCT(Point-of-Care Test) 시장은 특히 분산된 헬스케어 환경에서 신속한 진단 솔루션에 대한 수요 증가로 인해 큰 변화의 시기를 맞이하고 있습니다. 시장 규모는 2024년 4,648만 달러에서 예측 기간 동안 7.33%의 연평균 복합 성장률(CAGR)로 성장하여 2033년에는 8,555만 달러에 달할 것으로 예측됩니다. 당뇨병, 심혈관 질환과 같은 만성질환의 유병률 증가와 더불어 감염성 질환의 신속한 진단에 대한 니즈가 시장 확대를 견인하고 있습니다.

많은 의료기관들이 기존의 중앙 검사실형 검사에서 보다 빠른 의사결정과 높은 접근성을 실현하는 POCT로 전환하고 있습니다. 이러한 변화는 도입률에서도 나타나고 있는데, POCT를 도입한 의료기관은 2020년 4만 2,000곳에서 2024년 6만 8,000곳으로 증가했습니다. 이러한 진화를 통해 실시간 환자 데이터 분석이 가능해졌고, 특히 당뇨병 관리, 심장질환 이벤트 모니터링, 응급상황 치료에서 중요한 역할을 하고 있습니다.

시장 세분화

제품별로는 반복적으로 사용되는 특성과 진단에 필수적인 검사 키트 및 소모품 부문이 시장을 주도하고 있으며, 점유율은 65.55%에 달할 전망입니다. 여기에는 포도당 검사 스트립(128억 달러), 측면 흐름 카트리지(84억 달러), 응고 모니터링 키트 등이 포함됩니다. 이들은 일상 검사부터 긴급 검사까지 폭넓게 사용되고 있으며, 지속적인 수익원이 되고 있습니다. 또한, 제조 기술의 발전으로 비용 절감과 접근성 확대가 이루어지고 있습니다.

검사 유형별로는 면역학적 POCT가 시장을 지배하고 있으며, 전 세계 매출의 41.41% 이상을 차지하고 있습니다. 이 검사들은 HIV, 간염, 심장질환 등의 신속한 현장 진단을 가능하게 합니다. 사용 편의성과 비용 효율성(테스트 당 2.85달러 정도)으로 인해 도시 지역과 의료 서비스가 부족한 지역 모두에서 신속한 진단의 기반이 되고 있습니다.

적응증별로는 감염성 질환이 주요 용도이며, 시장의 31.30% 이상을 차지합니다. 호흡기 감염, HIV, 간염과 같은 질병의 높은 발생률과 대규모 검사에 대한 공중 보건의 요구는 이 분야의 우위를 더욱 공고히 하고 있습니다. 2024년에는 전 세계적으로 28억 건 이상의 호흡기 검사와 14억 건 이상의 위장관계 병원체 검사가 실시되었습니다.

지역별 인사이트

북미

북미는 2024년 매출 186억 4,882만 달러가 넘는 세계 리더로, 광범위한 보험 적용 범위와 탄탄한 의료 인프라를 기반으로 하고 있습니다. 특히 미국은 23만 8,000개의 의사 사무실에서 연간 18억 건의 검사를 시행하는 최대 시장입니다. 주요 연구기관과 정부기관의 대규모 투자가 지속적인 기술 발전과 시장 침투를 보장하고 있습니다.

아시아태평양

아시아태평양은 가장 빠르게 성장하는 지역으로 CAGR이 8.27%에 달할 전망입니다. 중국, 인도, 일본, 동남아시아 등의 국가에서 의료 현대화는 대규모 정부 자금에 의해 촉진되고 있습니다. 예를 들어, 인도의 Ayushman Bharat 제도는 5억 명 이상의 국민에게 서비스를 제공하고 있으며, 대량의 POCT 수요를 창출하고 있습니다. 또한, 현지 생산과 민관협력을 통해 지역의 역량이 더욱 강화되고 있습니다.

유럽

유럽 국가들도 EU 입찰, 중앙집중형 의료 이니셔티브, 항균제 내성 검사의 광범위한 도입 등을 통해 노력을 강화하고 있습니다. 독일, 프랑스, 영국 등의 국가들은 보편적 의료보험제도나 혁신 보조금을 통해 POCT에 대한 접근성을 높이고 있습니다.

세계의 POCT(Point-of-Care Test) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추이 및 예측, 각종 분류별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 전해드립니다.

영문목차

The global Point-of-Care Testing (POCT) Market is undergoing a significant transformation, driven by the rising demand for rapid diagnostic solutions, especially in decentralized healthcare environments. Valued at US$ 46.48 million in 2024, the market is forecast to reach US$ 85.55 million by 2033, growing at a CAGR of 7.33% between 2025 and 2033. The accelerating prevalence of chronic illnesses such as diabetes and cardiovascular disorders, combined with the need for swift diagnosis of infectious diseases, is propelling market expansion.

A growing number of healthcare facilities are transitioning from centralized lab-based testing to POCT for faster decision-making and greater accessibility. The adoption rate reflects this shift, with 68,000 healthcare sites worldwide integrating POCT in 2024, compared to 42,000 in 2020. This evolution enables real-time patient data analysis, particularly critical in managing diabetes, monitoring cardiac events, and administering treatment during emergencies.

Noteworthy Market Developments

The year 2024 saw 67 new POCT devices cleared by the FDA, a testament to the market's innovation momentum. Several of these solutions are equipped with AI capabilities and integrated with Electronic Health Records (EHRs) to streamline clinical workflows. Multiplex assays capable of detecting multiple pathogens from a single sample are also revolutionizing diagnostics by reducing testing complexity and result turnaround time.

Concurrently, the at-home testing segment is expanding rapidly, supported by regulatory endorsements such as the FDA's clearance of an over-the-counter dual test for influenza and COVID-19 in early 2025. Companies are investing in developing portable PCR-based systems and mobile diagnostics suited for emergency and rural environments. The direct-to-consumer market alone is expected to grow from US$ 7.8 billion in 2025 to over US$ 11.8 billion by 2035.

Strategic partnerships, acquisitions, and technology funding have shaped a competitive environment where companies such as Roche, Abbott, and Danaher are not only consolidating their market position but also pioneering advanced diagnostics through AI, cloud connectivity, and miniaturized devices.

Core Growth Drivers

Chronic Disease Burden: Increasing global incidence of diabetes, cardiovascular disorders, and infectious diseases demanding continual monitoring.
Rapid Diagnostics Demand: Emergency and remote settings necessitate quicker turnaround times, fueling POCT adoption.
Technological Integration: AI, cloud computing, and smartphone compatibility are enhancing test accuracy and accessibility.
Regulatory Acceleration: Government incentives and expedited device approvals are encouraging market entry and innovation.
Decentralized Healthcare Models: Shifting care delivery to homes, pharmacies, and community health centers is creating sustained demand.

Emerging Technology Trends

AI in Diagnostics: Integration of machine learning to interpret results and guide clinical decisions is becoming a standard feature in new POCT devices.
Multiplex POCT Assays: Advanced tests that detect multiple biomarkers in one go are growing at a projected rate of 25%.
Smartphone Connectivity: The number of devices linked to smartphones is set to increase by 30%, facilitating remote care models.
Cloud-Based Reporting: The use of cloud platforms for real-time result sharing and storage is expected to grow by 35% over the next few years.
Miniaturized Platforms: Portable diagnostics, such as mobile CT and PCR devices, are making POCT viable even in ambulances and rural settings.

Barriers to Optimization

High Cost of Advanced Devices: AI-integrated and multiplex systems come with significant capital and operational expenses.
Training and Standardization Gaps: Ensuring accuracy in non-laboratory environments remains a challenge due to variability in user expertise.
Regulatory Complexity Across Regions: Diverse regulations for OTC vs. prescription-based testing can complicate global product rollouts.
Data Security: The rise in cloud-based diagnostics raises cybersecurity concerns related to patient data.

Market Segment Analysis

The Testing Kits & Consumables category leads the market with a 65.55% share, driven by their recurring nature and indispensable use in diagnostics. These include high-demand items like glucose test strips (US$ 12.8 billion), lateral flow cartridges (US$ 8.4 billion), and coagulation monitoring kits. Their role in routine and emergency testing ensures a continuous revenue stream, with advanced manufacturing helping reduce costs and widen accessibility.

From a test-type perspective, Immunological PoC Tests dominate the landscape, contributing over 41.41% of global revenue. These tests enable fast, point-of-use diagnosis of conditions like HIV, hepatitis, and cardiac diseases. Their ease of use and cost-effectiveness (as low as US$ 2.85/test) have made them the cornerstone of rapid diagnostics in both urban and underserved settings.

In terms of indication, Infectious Diseases remain the primary application, accounting for over 31.30% of the market. High incidence rates of conditions like respiratory infections, HIV, and hepatitis, combined with public health mandates for mass testing, reinforce this segment's leadership. More than 2.8 billion respiratory tests and 1.4 billion gastrointestinal pathogen tests were conducted globally in 2024.

Additionally, Prescription-Based Testing remains the dominant mode, holding a 53.25% share. These tests, such as HbA1c and metabolic panels, require physician oversight and are tightly integrated into insurance reimbursement and regulatory frameworks, ensuring quality and proper clinical guidance.

Market Segmentation

By Product

Devices & Instruments
Diagnostic Analyzers & Testing Devices
Blood Gas & Electrolyte Analyzers
Cardiac Biomarker Analyzers
Glucose Monitoring Devices
Coagulation Testing Analyzers
Urinalysis Analyzers
Routine Clinical Chemistry Analyzers
Others
Monitoring Devices
Blood Pressure Monitors
Thermometers
Pulse Oximeters
Others
Testing Kits & Consumables
Blood Gas & Electrolyte Test Kits
Cardiac Biomarker Test Kits
Routine Clinical Chemistry Test Kits
Hematology Test Kits Coagulation Testing Kits
Urinalysis Test Strips & Kits
Cholesterol Test Strips
Drugs Abuse Testing Kits
Pregnancy And Fertility Testing Kits
Others

By Test Type

Immunological PoC Tests
Nucleic Acid-Based PoC Tests
Biomarker-Based PoC Tests

By Indication

Infectious Diseases
HIV
COVID-19
Others
Oncology
Cardiovascular Diseases
Metabolic Disorders
Respiratory Diseases
Neurological Disorders
Gastrointestinal Disorders
Others

By Technology

Biosensor Technology
Microfluidic Lab-On-A-Chip Technology
Molecular Diagnostics
Immunoassays
Others

By Sample Type

Blood
Urine
Saliva
Others

By Mode Of Purchase

Prescription-based Testing
Over the Counter (OTC) Testing

By End User

Hospitals & Clinics
Diagnostic Centers
Homecare Settings
Research Laboratories
Others

By Distribution Channel

Direct Distribution
Retail Pharmacies
Online Pharmacies
Others

Geographic Insights

North America

North America stands as the global leader, with 2024 revenue exceeding US$ 18,648.82 million, supported by extensive insurance coverage and robust healthcare infrastructure. The U.S., in particular, is the top-performing country, conducting 1.8 billion annual tests across 238,000 physician offices. Massive investment from leading institutions and government bodies ensures continued technological advancement and market penetration.

Asia Pacific

Asia Pacific is the fastest-growing region with a CAGR of 8.27%. Healthcare modernization across countries such as China, India, Japan, and Southeast Asia is bolstered by massive government funding. For instance, India's Ayushman Bharat scheme serves over 500 million citizens, driving high-volume POCT demand. Local manufacturing and public-private partnerships further amplify regional capabilities.

Europe

European nations are also ramping up efforts through EU tenders, centralized healthcare initiatives, and widespread adoption of antimicrobial resistance testing. Countries like Germany, France, and the UK are enhancing POCT accessibility through universal health schemes and innovation grants.

By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Hungary
Rest of Eastern Europe
Asia Pacific
China
India
Japan
South Korea
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East
UAE
Saudi Arabia
Bahrain
Kuwait
Qatar
Rest of Middle East
Africa
Morocco
Egypt
Nigeria
South Africa
Rest of Africa
South America
Argentina
Brazil
Rest of South America

Leading Market Participants

Abbott Laboratories
F. Hoffmann-La Roche Ltd
Danaher Corporation
Becton, Dickinson and Company (BD)
bioMerieux SA
Bio-Rad Laboratories, Inc.
Other Prominent Players

Table of Content

Chapter 1. Research Framework

1.1. Research Objective
1.2. Type Overview
1.3. Market Segmentation

Chapter 2. Research Methodology

2.1. Qualitative Research
- 2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
- 2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.4. Assumption for the Study
2.5. Market Size Estimation
2.6. Data Triangulation

Chapter 3. Executive Summary: Global Point-of-Care Testing Market

Chapter 4. Global Point-of-Care Testing Market Overview

4.1. Industry Value Chain Analysis
- 4.1.1. Material Provider
- 4.1.2. Manufacturer
- 4.1.3. Distributor
- 4.1.4. End User
4.2. Industry Outlook
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of Substitutes
- 4.4.4. Threat of New Entrants
- 4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
- 4.5.1. Growth Drivers
- 4.5.2. Restraints
- 4.5.3. Opportunities
- 4.5.4. Key Trends
4.6. Market Growth and Outlook
- 4.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2033
- 4.6.2. Price Trend Analysis
4.7. Competition Dashboard
- 4.7.1. Market Concentration Rate
- 4.7.2. Company Market Share Analysis (Value %), 2024
- 4.7.3. Competitor Mapping & Benchmarking
4.8. Actionable Insights (Analyst's Recommendations)

Chapter 5. Global Point-of-Care Testing Market Analysis, By Product

5.1. Key Insights
5.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 5.2.1. Devices & Instruments
  - 5.2.1.1. Diagnostic Analyzers & Testing Devices
    - 5.2.1.1.1. Blood Gas & Electrolyte Analyzers
    - 5.2.1.1.2. Cardiac Biomarker Analyzers
    - 5.2.1.1.3. Glucose Monitoring Devices
    - 5.2.1.1.4. Coagulation Testing Analyzers
    - 5.2.1.1.5. Urinalysis Analyzers
    - 5.2.1.1.6. Routine Clinical Chemistry Analyzers
    - 5.2.1.1.7. Others
  - 5.2.1.2. Monitoring Devices
    - 5.2.1.2.1. Blood Pressure Monitors
    - 5.2.1.2.2. Thermometers
    - 5.2.1.2.3. Pulse Oximeters
    - 5.2.1.2.4. Others
- 5.2.2. Testing Kits & Consumables
  - 5.2.2.1. Blood Gas & Electrolyte Test Kits
  - 5.2.2.2. Cardiac Biomarker Test Kits
  - 5.2.2.3. Routine Clinical Chemistry Test Kits
  - 5.2.2.4. Hematology Test Kits Coagulation Testing Kits
  - 5.2.2.5. Urinalysis Test Strips & Kits
  - 5.2.2.6. Cholesterol Test Strips
  - 5.2.2.7. Drugs Abuse Testing Kits
  - 5.2.2.8. Pregnancy And Fertility Testing Kits
  - 5.2.2.9. Others

Chapter 6. Global Point-of-Care Testing Market Analysis, By Test Type

6.1. Key Insights
6.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 6.2.1. Immunological PoC Tests
- 6.2.2. Nucleic Acid-Based PoC Tests
- 6.2.3. Biomarker-Based PoC Tests

Chapter 7. Global Point-of-Care Testing Market Analysis, By Indication

7.1. Key Insights
7.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 7.2.1. Infectious Diseases
  - 7.2.1.1. HIV
  - 7.2.1.2. COVID-19
  - 7.2.1.3. Others
- 7.2.2. Oncology
- 7.2.3. Cardiovascular Diseases
- 7.2.4. Metabolic Disorders
- 7.2.5. Respiratory Diseases
- 7.2.6. Neurological Disorders
- 7.2.7. Gastrointestinal Disorders
- 7.2.8. Others

Chapter 8. Global Point-of-Care Testing Market Analysis, By Technology

8.1. Key Insights
8.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 8.2.1. Biosensor Technology
- 8.2.2. Microfluidic Lab-On-A-Chip Technology
- 8.2.3. Molecular Diagnostics
- 8.2.4. Immunoassays
- 8.2.5. Others

Chapter 9. Global Point-of-Care Testing Market Analysis, By Sample Type

9.1. Key Insights
9.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 9.2.1. Blood
- 9.2.2. Urine
- 9.2.3. Saliva
- 9.2.4. Others

Chapter 10. Global Point-of-Care Testing Market Analysis, By Mode of Purchase

10.1. Key Insights
10.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 10.2.1. Prescription-based Testing
- 10.2.2. Over the Counter (OTC) Testing

Chapter 11. Global Point-of-Care Testing Market Analysis, By End User

11.1. Key Insights
11.2. Market Size and Forecast, 2020-2033 (US$ Mn)

Chapter 12. Global Point-of-Care Testing Market Analysis, By Distribution Channel

12.1. Key Insights
12.2. Market Size and Forecast, 2020-2033 (US$ Mn)

Chapter 13. Global Point-of-Care Testing Market Analysis, By Region

13.1. Key Insights
13.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 13.2.1. North America
  - 13.2.1.1. The U.S.
  - 13.2.1.2. Canada
  - 13.2.1.3. Mexico
- 13.2.2. Europe
  - 13.2.2.1. Western Europe
    - 13.2.2.1.1. The UK
    - 13.2.2.1.2. Germany
    - 13.2.2.1.3. France
    - 13.2.2.1.4. Italy
    - 13.2.2.1.5. Spain
    - 13.2.2.1.6. Rest of Western Europe
  - 13.2.2.2. Eastern Europe
    - 13.2.2.2.1. Poland
    - 13.2.2.2.2. Russia
    - 13.2.2.2.3. Rest of Eastern Europe
- 13.2.3. Asia Pacific
  - 13.2.3.1. China
  - 13.2.3.2. India
  - 13.2.3.3. Japan
  - 13.2.3.4. South Korea
  - 13.2.3.5. Australia & New Zealand
  - 13.2.3.6. ASEAN
  - 13.2.3.7. Rest of Asia Pacific
- 13.2.4. Middle East & Africa
  - 13.2.4.1. UAE
  - 13.2.4.2. Saudi Arabia
  - 13.2.4.3. South Africa
  - 13.2.4.4. Rest of MEA
- 13.2.5. South America
  - 13.2.5.1. Argentina
  - 13.2.5.2. Brazil
  - 13.2.5.3. Rest of South America

Chapter 14. North America Point-of-Care Testing Market Analysis

14.1. Key Insights
14.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 14.2.1. By Product
- 14.2.2. By Test Type
- 14.2.3. By Indication
- 14.2.4. By Technology
- 14.2.5. By Sample Type
- 14.2.6. By Mode of Purchase
- 14.2.7. By End User
- 14.2.8. By Distribution Channel
- 14.2.9. By Country

Chapter 15. Europe Point-of-Care Testing Market Analysis

15.1. Key Insights
15.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 15.2.1. By Product
- 15.2.2. By Test Type
- 15.2.3. By Indication
- 15.2.4. By Technology
- 15.2.5. By Sample Type
- 15.2.6. By Mode of Purchase
- 15.2.7. By End User
- 15.2.8. By Distribution Channel
- 15.2.9. By Country

Chapter 16. Asia Pacific Point-of-Care Testing Market Analysis

16.1. Key Insights
16.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 16.2.1. By Product
- 16.2.2. By Test Type
- 16.2.3. By Indication
- 16.2.4. By Technology
- 16.2.5. By Sample Type
- 16.2.6. By Mode of Purchase
- 16.2.7. By End User
- 16.2.8. By Distribution Channel
- 16.2.9. By Country

Chapter 17. Middle East & Africa Point-of-Care Testing Market Analysis

17.1. Key Insights
17.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 17.2.1. By Product
- 17.2.2. By Test Type
- 17.2.3. By Indication
- 17.2.4. By Technology
- 17.2.5. By Sample Type
- 17.2.6. By Mode of Purchase
- 17.2.7. By End User
- 17.2.8. By Distribution Channel
- 17.2.9. By Country

Chapter 18. South America Point-of-Care Testing Market Analysis

18.1. Key Insights
18.2. Market Size and Forecast, 2020-2033 (US$ Mn)
- 18.2.1. By Product
- 18.2.2. By Test Type
- 18.2.3. By Indication
- 18.2.4. By Technology
- 18.2.5. By Sample Type
- 18.2.6. By Mode of Purchase
- 18.2.7. By End User
- 18.2.8. By Distribution Channel
- 18.2.9. By Country

Chapter 19. Company Profile (Company Overview, Financial Matrix, Key Type landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

19.1. Abbott Laboratories
19.2. F. Hoffmann-La Roche Ltd
19.3. Danaher Corporation
19.4. Becton, Dickinson and Company (BD)
19.5. bioMerieux SA
19.6. Bio-Rad Laboratories, Inc.
19.7. Other Prominent Players

Chapter 20. Annexure

20.1. List of Secondary Sources
20.2. Key Country Markets - Marco Economic Outlook/Indicators

한글목차

목차

제1장 조사 프레임워크

제2장 조사 방법

제3장 주요 요약 : 세계의 POCT(Point-of-Care Testing) 시장

제4장 세계의 POCT(Point-of-Care Testing) 시장 : 개요

제5장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 제품별

제6장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 검사 유형별

제7장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 적응증별

제8장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 기술별

제9장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 샘플 유형별

제10장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 구입 형태별

제11장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 최종사용자별

제12장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 유통 채널별

제13장 세계의 POCT(Point-of-Care Testing) 시장 분석 : 지역별

제14장 북미의 POCT(Point-of-Care Testing) 시장 분석

제15장 유럽의 POCT(Point-of-Care Testing) 시장 분석

제16장 아시아태평양의 POCT(Point-of-Care Testing) 시장 분석

제17장 중동 및 아프리카의 POCT(Point-of-Care Testing) 시장 분석

제18장 남미의 POCT(Point-of-Care Testing) 시장 분석

제19장 기업 개요

제20장 부록